Verve Therapeutics, INC

Eli Lilly and Company has successfully completed its tender offer and subsequent merger to acquire Verve Therapeutics, Inc., making Verve a wholly-owned subsidiary.

Verve Therapeutics, Inc. has implemented a retention bonus program for its Chief Financial Officer and Chief Operating Officer/General Counsel, totaling over $900,000, as the company progresses towards its acquisition by Eli Lilly and Company.

Eli Lilly and Company has announced a definitive agreement to acquire Verve Therapeutics, a clinical-stage gene editing company, for an upfront cash payment of $10.50 per share plus a contingent value right of up to $3.00 per share.

Verve Therapeutics, Inc. announced that its stockholders approved all three proposals at the Annual Meeting held on June 5, 2025, including the election of Class I directors, ratification of Ernst & Young LLP as auditor, and advisory approval of executive compensation.

Verve Therapeutics announces positive initial data from its Heart-2 Phase 1b clinical trial of VERVE-102, demonstrating dose-dependent LDL-C reductions, and reports a cash runway into mid-2027.

Verve Therapeutics reports positive initial safety and efficacy data from its Heart-2 Phase 1b clinical trial of VERVE-102, showing dose-dependent reductions in LDL-C in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease.

Verve Therapeutics reports increased collaboration revenue and provides updates on its clinical programs in its Q1 2025 financial results.

Verve Therapeutics reports a net loss of $50.1 million for the third quarter of 2024, while advancing its clinical programs for gene editing therapies.

Verve Therapeutics reports a net loss of $98.5 million for the first half of 2024, while advancing its gene editing programs and initiating a Phase 1b clinical trial for VERVE-102.

Verve Therapeutics reports a net loss of $48.7 million for the first quarter of 2024, while advancing its gene editing programs and pausing enrollment in the Heart-1 trial.

Verve Therapeutics details its financial performance for 2024 and offers updates on its gene editing programs targeting cardiovascular disease.

Verve Therapeutics updates its employment agreement with its Chief Scientific Officer and files its annual report on Form 10-K, detailing its financial performance and clinical trial progress.

GV entities, including Alphabet Inc., reported the disposition of all their common stock in Verve Therapeutics, Inc. following the completion of Eli Lilly and Company's tender offer and subsequent merger.

Verve Therapeutics director Michael F. MacLean's stock options were cancelled and converted to cash and contingent value rights as a result of the merger with Eli Lilly and Company.

Verve Therapeutics, Inc. has completed its merger with Eli Lilly and Company, becoming a wholly-owned subsidiary, with shareholders receiving cash and contingent value rights.

Verve Therapeutics' Chief Financial Officer, Allison Dorval, reported the conversion of her equity holdings into cash and contingent value rights following the company's acquisition by Eli Lilly and Company.

Verve Therapeutics' Chief Administrative Officer, Joan Nickerson, disposed of all common stock, stock options, and restricted stock units following the company's acquisition by Eli Lilly and Company.

Verve Therapeutics, Inc. CEO Sekar Kathiresan has disposed of all his direct and indirect equity and derivative holdings in the company following the completion of its merger with Eli Lilly and Company's subsidiary.

Verve Therapeutics announces its annual meeting of stockholders to be held on June 5, 2025, with key proposals including the election of directors and ratification of the accounting firm.

Verve Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to vote on director elections, auditor ratification, executive compensation, and other business.

Verve Therapeutics will hold its annual meeting of stockholders on June 6, 2024, to elect directors, ratify the appointment of Ernst & Young LLP, and vote on executive compensation.

Verve Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, auditor ratification, executive compensation, and other matters.

Pentwater Capital Management LP and Matthew Halbower have disclosed a 7.5% beneficial ownership stake in Verve Therapeutics, Inc.

Multiple GV entities, including those affiliated with Alphabet Inc., have reported zero beneficial ownership in Verve Therapeutics, Inc. after its acquisition by Eli Lilly and Company.

Millennium Management LLC and its affiliates have reported a reduction in their beneficial ownership of Verve Therapeutics, Inc. common stock, falling below the 5% reporting threshold after briefly exceeding it.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in Verve Therapeutics, Inc. as of March 31, 2025.

State Street Corporation has filed a Schedule 13G, reporting a 3.8% passive beneficial ownership stake in Verve Therapeutics Inc. as of December 31, 2024.

Integrated Core Strategies (US) LLC and Millennium Management entities, including Israel A. Englander, have filed an amended Schedule 13G disclosing beneficial ownership of less than 5% in Verve Therapeutics, Inc. as of December 31, 2024.